Barely months after reporting another successful year of record revenues and record earnings, Catalyst Pharmaceuticals Inc. (CPRX) has agreed to be acquired by Italy's Angelini Pharma S.p.A, for US$31.50 per share or a total equity value of US$4.1 billion.
Catalyst has a robust portfolio of products focused on the treatment of rare neuromuscular and neurological diseases. It markets Lambert-Eaton myasthenic syndrome drug FIRDAPSE, Duchenne Muscular Dystrophy drug AGAMREE, and antiepileptic drug FYCOMPA, the U.S. rights to which were acquired from Eisai in 2023.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com